

Practical Gynecology, 2nd Edition – Chapter 15 References

1. **Soules MR, Sherman S, Parrott E, Rebar R.** Executive summary: Stages or reproductive aging workshop. *Fertil Steril.* 2001;76:874.
2. **Parker WH, Broder MS, Liu Z, et al.** Ovarian conservation at the time of hysterectomy for benign disease. *Clinic Obstet Gynecol.* 2007;50:354-61.
3. **Santoro NF.** Endocrinology of the climacteric. In: Seifer DB, Kennard EA, eds. *Menopause: Endocrinology and Management* Totowa, NJ: Humana Press; 1999:21-34.
4. **Avis NE, Stellato R, Crawford S, et al.** Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. *Social Science & Medicine.* 2001;52:345-56.
5. **Rapkin AJ.** Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. *Am J Obstet & Gynecol.* 2007;196:97-106. *Excellent discussion of the pathophysiology of hot flashes and centrally acting medications used to treat them.*
6. **Grady D.** Management of Menopausal Symptoms. *N Engl J Med.* 2006;355;22:2338-2346.
7. **Jackson SL, Scholes D, Boyko EJ, et al.** Predictors of Urinary Incontinence in Postmenopausal Women. *Obstet Gynecol.* 2006;108:855-62.
8. **Harris SS, Link CL, Tennstedt SL, et al.** Care seeking and treatment for urinary incontinence in a diverse population. *J Urol.* 2007;177:680-84.
9. **Hendrix SL, Cochrane BB, Nygaard IE, et al.** Effects of estrogen with and without progestin on urinary incontinence. *JAMA.* 2005;293:935-48.
10. **Grady D, Brown JS, Vittinghoff E, et al.** Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. *Obstet Gynecol.* 2001;97:116-20.
11. **Bromberger JT, Meyer PM, Kravitz HM, et al.** Psychologic distress and natural menopause: A multiethnic community study. *Amer J Public Health.* 2001;91:1435-42.
12. **Cohen LS, Soares CN, Vitonis AF, et al.** Risk for new onset of depression during the menopausal transition. *Arch Gen Psychiatry* 2006;63:385-90.
13. **National Osteoporosis Foundation.** America's bone health: the state of osteoporosis and low bone mass in our nation. Washington DC: National Osteoporosis Foundation, 2002.

14. **Burge R, Dawson-Hughes B, Solomon DH, et al.** Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res* 2007;22:465-75.
15. **Oden A, et al.** Lifetime risk of hip fractures is underestimated. *Osteoporosis Int.* 1998;8:599-603
16. **Mosca L, Banka CL, Benjamin EJ, et al.** Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation.* 2007;115:1481-1501. *AHA guidelines update for cardiac risk stratification and treatment of risk factors for women.*
17. **Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, et al.** Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. *JAMA.* 2006;295:2057-71.
18. **Wyon Y; Wijma K; Nedstrand E; Hammar MA.** Comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. *Climacteric.* 2004 Jun;7:153-64.
19. **Suckling J, Lethaby A, Kennedy R.** Local estrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev.* 2003/2005;(4):CD001500.
20. **Position statement: the role of local vaginal estrogen for the treatment of vaginal atrophy in postmenopausal women: 2007 position statement for the North American Menopause Society.** 2007;14:357-69. *Excellent evidence based review of atrophic vaginitis.*
21. **Geller SE, Studee L.** Botanical and dietary supplements for mood and anxiety in menopausal women. *Menopause.* 2007;14:541-49. *Comprehensive review of herbal treatment for depression and anxiety during menopause.*
22. **Rosen CJ.** Postmenopausal osteoporosis. *N Engl J Med.* 2005;353:595-603. *Excellent summary of issues surrounding treatment of postmenopausal osteoporosis.*
23. **Writing group for the Women's Health Initiative investigators.** Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* 2002;288:321-33.
24. **Black DM, Schwartz AV, Ensrud KE, et al.** FLEX research group effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. *JAMA.* 2006; 296:2927-2938.
25. **American Association of Clinical Endocrinologists.** AACE medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. *Endocrine Practice.* 2003;9:544-64.

26. **North American Menopause Society.** Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. *Menopause*.2006;9:84-101